ATE464304T1 - Carboxamid-spirolactam-cgrp-rezeptor-antagonist n - Google Patents
Carboxamid-spirolactam-cgrp-rezeptor-antagonist nInfo
- Publication number
- ATE464304T1 ATE464304T1 AT05795301T AT05795301T ATE464304T1 AT E464304 T1 ATE464304 T1 AT E464304T1 AT 05795301 T AT05795301 T AT 05795301T AT 05795301 T AT05795301 T AT 05795301T AT E464304 T1 ATE464304 T1 AT E464304T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- carboxamide
- receptor antagonist
- cgrp receptor
- compounds
- Prior art date
Links
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 title 1
- 150000003857 carboxamides Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 2
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 abstract 2
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 abstract 1
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 abstract 1
- 208000006561 Cluster Headache Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000018912 cluster headache syndrome Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60943604P | 2004-09-13 | 2004-09-13 | |
| PCT/US2005/032036 WO2006031606A2 (en) | 2004-09-13 | 2005-09-09 | Carboxamide spirolactam cgrp receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE464304T1 true ATE464304T1 (de) | 2010-04-15 |
Family
ID=36060551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05795301T ATE464304T1 (de) | 2004-09-13 | 2005-09-09 | Carboxamid-spirolactam-cgrp-rezeptor-antagonist n |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7390798B2 (de) |
| EP (1) | EP1796678B1 (de) |
| JP (1) | JP5039553B2 (de) |
| CN (1) | CN101448821B (de) |
| AT (1) | ATE464304T1 (de) |
| AU (1) | AU2005285197B2 (de) |
| CA (1) | CA2579840C (de) |
| DE (1) | DE602005020655D1 (de) |
| WO (1) | WO2006031606A2 (de) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1179995B1 (de) | 1999-05-11 | 2007-01-31 | Atrionix, Inc. | Ballonverankerungsdraht |
| US7205293B2 (en) * | 2003-03-14 | 2007-04-17 | Merck & Co., Inc. | Benodiazepine spirohydantoin CGRP receptor antagonists |
| CA2580020A1 (en) * | 2004-09-09 | 2006-03-23 | Ian M. Bell | Aryl spirolactam cgrp receptor antagonists |
| ATE518852T1 (de) * | 2004-09-13 | 2011-08-15 | Merck Sharp & Dohme | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten |
| CA2579847A1 (en) * | 2004-09-13 | 2006-03-23 | Merck & Co., Inc. | Bicyclic anilide spirolactam cgrp receptor antagonists |
| WO2007061677A2 (en) * | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirolactam aryl cgrp receptor antagonists |
| ATE493412T1 (de) * | 2005-11-18 | 2011-01-15 | Merck Sharp & Dohme | Spirohydantoin-aryl-cgrp-rezeptorantagonisten |
| WO2007061692A2 (en) | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirolactam tricyclic cgrp receptor antagonists |
| WO2007061694A2 (en) | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirohydantoin tricyclic cgrp receptor antagonists |
| WO2007120589A2 (en) * | 2006-04-10 | 2007-10-25 | Merck & Co., Inc. | Process for the preparation of caprolactam cgrp antagonist intermediate |
| ATE517903T1 (de) | 2006-05-02 | 2011-08-15 | Bristol Myers Squibb Co | Verbindungen mit eingeschränkter konformation als cgrp rezeptor antagonisten. |
| US7470680B2 (en) * | 2006-05-03 | 2008-12-30 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| CA2650932C (en) * | 2006-05-09 | 2013-01-22 | Merck & Co., Inc. | Substituted spirocyclic cgrp receptor antagonists |
| JP5511379B2 (ja) * | 2006-07-21 | 2014-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃｇｒｐレセプターアンタゴニスト |
| US7951795B2 (en) * | 2006-12-08 | 2011-05-31 | Merck Sharp & Dohme Corp. | Constrained spirocyclic compounds as CGRP receptor antagonists |
| JP2010523663A (ja) * | 2007-04-11 | 2010-07-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 第３級アミド、スルホンアミド、カルバミン酸及び尿素末端基をもつｃｇｒｐ受容体アンタゴニスト |
| AU2008241488A1 (en) * | 2007-04-16 | 2008-10-30 | Merck Sharp & Dohme Corp. | Bicyclic anilide heterocyclic CGRP receptor antagonists |
| EP2146712A4 (de) * | 2007-04-16 | 2010-10-13 | Merck Sharp & Dohme | Heterocyclische aryl-cgrp-rezeptorantagonisten |
| JP5511657B2 (ja) * | 2007-06-05 | 2014-06-04 | メルク・シャープ・アンド・ドーム・コーポレーション | カルボキサミドヘテロ環式ｃｇｒｐ受容体アンタゴニスト |
| WO2008153852A1 (en) * | 2007-06-07 | 2008-12-18 | Merck & Co., Inc. | Tricyclic anilide heterocyclic cgrp receptor antagonists |
| JP2011512410A (ja) * | 2008-02-19 | 2011-04-21 | メルク・シャープ・エンド・ドーム・コーポレイション | イミダゾベンゾアゼピンｃｇｒｐ受容体アンタゴニスト |
| JP2010043063A (ja) * | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
| CA2734168A1 (en) | 2008-08-18 | 2010-02-25 | Merck Sharp & Dohme Corp. | 3- and 6-quinolines with n-attached heterocyclic cgrp receptor antagonists |
| JP2013542261A (ja) | 2010-11-12 | 2013-11-21 | メルク・シャープ・アンド・ドーム・コーポレーション | ピペリジノンカルボキサミドインダンｃｇｒｐ受容体アンタゴニスト |
| TWI487706B (zh) | 2010-11-12 | 2015-06-11 | Merck Sharp & Dohme | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| EP2654423B1 (de) * | 2010-12-22 | 2016-12-07 | Merck Sharp & Dohme Corp. | Kondensierte heterocyclische azaindan-carboxamid-cgrp-rezeptorantagonisten |
| EP2654421B1 (de) * | 2010-12-22 | 2016-10-19 | Merck Sharp & Dohme Corp. | Kondensierte heterocyclische indan-carboxamid-verbindungen als grp-rezeptorantagonisten |
| EP2554539B1 (de) | 2011-08-02 | 2014-12-10 | Universität Potsdam | Verfahren zur Herstellung von gamma-Spirolactamen aus zyklischen ungesättigten Carbonsäuren |
| EP2841417A1 (de) | 2012-04-26 | 2015-03-04 | Francis Xavier Tavares | Synthese von lactamen |
| US9174989B2 (en) * | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| EP2846800A4 (de) * | 2012-05-09 | 2015-11-11 | Merck Sharp & Dohme | Heterocyclische cgrp-rezeptorantagonisten |
| WO2013169567A1 (en) * | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Spirolactam cgrp receptor antagonists |
| US9227973B2 (en) | 2012-05-09 | 2016-01-05 | Merck Sharp & Dohme Corp. | Pyridine CGRP receptor antagonists |
| KR20210153745A (ko) * | 2013-09-16 | 2021-12-17 | 머크 샤프 앤드 돔 코포레이션 | Cgrp 수용체 길항제를 위한 제제 |
| JP6491669B2 (ja) | 2014-02-05 | 2019-03-27 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｃｇｒｐ活性化合物の錠剤製剤 |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| GB201417707D0 (en) | 2014-10-07 | 2014-11-19 | Viral Ltd | Pharmaceutical compounds |
| TWI763630B (zh) | 2015-07-02 | 2022-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
| TW201718574A (zh) * | 2015-08-12 | 2017-06-01 | 美國禮來大藥廠 | Ｃｇｒｐ受體拮抗劑 |
| MA44007A (fr) | 2016-02-05 | 2018-12-19 | Denali Therapeutics Inc | Inhibiteurs du récepteur interagissant avec protéine kinase 1 |
| JP7106462B2 (ja) | 2016-07-01 | 2022-07-26 | ジー１ セラピューティクス， インコーポレイテッド | Ｎ－（ヘテロアリール）－ピロロ［３，２－ｄ］ピリミジン－２－アミンの合成 |
| EP3526219B1 (de) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclische pyridonlactame und verfahren zur verwendung davon |
| HRP20220636T1 (hr) | 2016-12-09 | 2022-07-22 | Denali Therapeutics Inc. | Spojevi korisni kao inhibitori ripk1 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| EP3366286A1 (de) | 2017-02-22 | 2018-08-29 | Johannes Keller | Verbindungen zur behandlung von sepsis |
| FI3645001T3 (fi) | 2017-06-29 | 2024-09-25 | G1 Therapeutics Inc | Git38:n morfisia muotoja ja niiden valmistusmenetelmiä |
| WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| RS67557B1 (sr) | 2018-08-24 | 2026-01-30 | Pharmacosmos Holding As | Unapređena sinteza 1,4-diazaspiro[5.5]undekan-3-ona |
| CN116390712A (zh) | 2020-07-29 | 2023-07-04 | 阿勒根制药国际有限公司 | 治疗偏头痛 |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| WO2023049920A1 (en) | 2021-09-27 | 2023-03-30 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
| IL314082A (en) | 2022-01-12 | 2024-09-01 | Denali Therapeutics Inc | Crystal forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazapin-3-yl)- H4- 1,2,4-triazole-3-carboxamide |
| WO2024134683A1 (en) * | 2022-12-21 | 2024-06-27 | Msn Laboratories Private Limited, R&D Center | Novel process for the preparation of intermediate compounds used in the treatment of migraine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307108A (en) * | 1979-12-26 | 1981-12-22 | Pfizer Inc. | Method for lowering sorbitol levels using spiro-imides |
| AU2001252270B2 (en) * | 2000-05-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Hydantoin-containing glucokinase activators |
| WO2004087648A2 (en) * | 2003-03-12 | 2004-10-14 | Sun Pharmaceutical Industries Limited | Stabilized phenytoin containing composition |
| US7205293B2 (en) | 2003-03-14 | 2007-04-17 | Merck & Co., Inc. | Benodiazepine spirohydantoin CGRP receptor antagonists |
| CA2518830A1 (en) | 2003-03-14 | 2004-09-30 | Merck & Co., Inc. | Carboxamide spirohydantoin cgrp receptor antagonists |
| CA2579847A1 (en) * | 2004-09-13 | 2006-03-23 | Merck & Co., Inc. | Bicyclic anilide spirolactam cgrp receptor antagonists |
-
2005
- 2005-02-09 US US11/660,798 patent/US7390798B2/en not_active Expired - Lifetime
- 2005-09-09 WO PCT/US2005/032036 patent/WO2006031606A2/en not_active Ceased
- 2005-09-09 AU AU2005285197A patent/AU2005285197B2/en not_active Ceased
- 2005-09-09 EP EP05795301A patent/EP1796678B1/de not_active Expired - Lifetime
- 2005-09-09 AT AT05795301T patent/ATE464304T1/de not_active IP Right Cessation
- 2005-09-09 JP JP2007531340A patent/JP5039553B2/ja not_active Expired - Fee Related
- 2005-09-09 DE DE602005020655T patent/DE602005020655D1/de not_active Expired - Lifetime
- 2005-09-09 CN CN2005800305244A patent/CN101448821B/zh not_active Expired - Fee Related
- 2005-09-09 CA CA2579840A patent/CA2579840C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006031606A3 (en) | 2007-08-09 |
| AU2005285197A1 (en) | 2006-03-23 |
| JP2008512480A (ja) | 2008-04-24 |
| AU2005285197B2 (en) | 2011-03-10 |
| CA2579840C (en) | 2012-03-20 |
| CN101448821A (zh) | 2009-06-03 |
| EP1796678B1 (de) | 2010-04-14 |
| EP1796678A2 (de) | 2007-06-20 |
| DE602005020655D1 (de) | 2010-05-27 |
| EP1796678A4 (de) | 2009-09-02 |
| WO2006031606A2 (en) | 2006-03-23 |
| US20070293470A1 (en) | 2007-12-20 |
| CN101448821B (zh) | 2013-03-27 |
| CA2579840A1 (en) | 2006-03-23 |
| JP5039553B2 (ja) | 2012-10-03 |
| US7390798B2 (en) | 2008-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE464304T1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonist n | |
| TW200505903A (en) | CGRP receptor antagonists | |
| NO20072435L (no) | CGRP-reseptorantagonister | |
| ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
| ATE394400T1 (de) | Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| EP1605936A4 (de) | Aryl-spirohydantoin-cgrp-rezeptor-antagonisten | |
| ATE535514T1 (de) | Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten | |
| EP1641423A4 (de) | Benzodiazepin-cgrp-rezeptor-antagonisten | |
| ATE537170T1 (de) | Cgrp-rezeptorantagonisten | |
| EP1606286A4 (de) | Benzodiazepinspirohydantoine als cgrp-rezeptorantagonisten | |
| WO2006029153A3 (en) | Monocyclic anilide spirolactam cgrp receptor antagonists | |
| WO2005000807A3 (en) | Benzodiazepine cgrp receptor antagonists | |
| ATE464305T1 (de) | Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors | |
| EP1794133A4 (de) | Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors | |
| DE602005027230D1 (de) | Cgrp-rezeptorantagonisten | |
| WO2006041830A3 (en) | Cgrp receptor antagonists | |
| DE602005027870D1 (de) | Cgrp-rezeptorantagonisten | |
| ATE466853T1 (de) | Cgrp-rezeptorantagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |